Osteoarthritis Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Osteoarthritis Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Osteoarthritis is a major debilitating form of joint disease and is more evident in geriatric population. The disease is slow gradual process, which leads to low quality of life, loss of functions, and moderate to severe pain, especially in population having low physical activity or with high body mass index (BMI).
Market Dynamics
Increasing prevalence of osteoarthritis is a major factor driving the osteoarthritis drugs market growth. According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2013, total prevalence of combined symptomatic and radiographic osteoarthritis of knee and hip was around 3.8% worldwide, with 20.3 % in males and 4.5% in females.
Furthermore, key players in the market are focused on research and development of medication for symptomatic treatment of osteoarthritis, which is expected to drive the market growth. For instance, in April 2018, Flexion Therapeutics, Inc. initiated Phase III study of FX006 32 mg indicated for knee osteoarthritis. The study in expected to be completed by June 2020.
However, use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen and naproxen in pain management of osteoarthritis can cause cardiovascular diseases, which in turn is expected to hinder the market growth. In June 2018, the European League against Rheumatism (EULAR) stated the risk of cardiovascular diseases with the regular use of NSAIDs in the treatment of osteoarthritis pain.
Key features of the study:
This report provides in-depth analysis of the osteoarthritis drugs market and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global osteoarthritis drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Pfizer Inc., Abbott, Eli Lilly and Company, ABIOGEN PHARMA S.p.A, Horizon Pharma plc., Ferring B.V., Merck Sharp & Dohme Corp., Medivir, Bioventus, Inc., Sanofi, Flexion Therapeutics, Inc., Regeneron, and GlaxoSmithKline Plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics.
The global osteoarthritis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the osteoarthritis drugs market
Detailed Segmentation:
Global Osteoarthritis Drugs Market, By Drug Class:
Analgesics
Nonsteroidal Anti-Inflammatory Drugs
Corticosteroids
Hyaluronic Acid
Phase III Drugs
Global Osteoarthritis Drugs Market, By Route of Administration:
Oral
Parenteral
Global Osteoarthritis Drugs Market, By Disease Type:
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
Global Osteoarthritis Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Osteoarthritis Drugs Market, By Region:
North America
By Drug Class:
Analgesics
Nonsteroidal Anti-Inflammatory Drugs
Corticosteroids
Hyaluronic Acid
Phase III Drugs
By Route of Administration:
Oral
Parenteral
By Disease Type:
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Class:
Analgesics
Nonsteroidal Anti-Inflammatory Drugs
Corticosteroids
Hyaluronic Acid
Phase III Drugs
By Route of Administration:
Oral
Parenteral
By Disease Type:
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
Analgesics
Nonsteroidal Anti-Inflammatory Drugs
Corticosteroids
Hyaluronic Acid
Phase III Drugs
By Route of Administration:
Oral
Parenteral
By Disease Type:
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Analgesics
Nonsteroidal Anti-Inflammatory Drugs
Corticosteroids
Hyaluronic Acid
Phase III Drugs
By Route of Administration:
Oral
Parenteral
By Disease Type:
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Class:
Analgesics
Nonsteroidal Anti-Inflammatory Drugs
Corticosteroids
Hyaluronic Acid
Phase III Drugs
By Route of Administration:
Oral
Parenteral
By Disease Type:
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Analgesics
Nonsteroidal Anti-Inflammatory Drugs
Corticosteroids
Hyaluronic Acid
Phase III Drugs
By Route of Administration:
Oral
Parenteral
By Disease Type:
Ankle Osteoarthritis
Hip Osteoarthritis
Knee Osteoarthritis
Shoulder Osteoarthritis
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Pfizer Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
Abbott
Eli Lilly and Company
ABIOGEN PHARMA S.p.A
Horizon Pharma plc.
Ferring B.V.
Merck Sharp & Dohme Corp.
Medivir
Bioventus, Inc.
Sanofi
Flexion Therapeutics, Inc.
Regeneron
GlaxoSmithKline Plc.
“*” marked represents similar segmentation in other categories in the respective section.